Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.32 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.32 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13256939 | 0.86 | GRIK1 (0.38) | ALDH1A1KDM4ETSHRTHPOGRIK1 | |
| SCHEMBL27520422 | 0.86 | GRIK1 (0.38) | ALDH1A1KDM4ETSHRTHPOGRIK1 | |
| SCHEMBL5798787 | 0.80 | ALDH1A1 (0.37) | ALDH1A1GLO1 | |
| SCHEMBL5798789 | 0.80 | ALDH1A1 (0.37) | ALDH1A1GLO1 | |
| SCHEMBL10743738 | 0.75 | GLO1 (0.64) | ALDH1A1KDM4EGLO1 | |
| SCHEMBL4681859 | 0.75 | GRIK1 (0.46) | ALDH1A1GRIK1GRIA2GRIA4GRIK3 | |
| SCHEMBL12368604 | 0.75 | — | — | |
| SCHEMBL5074746 | 0.75 | — | — | |
| SCHEMBL1323858 | 0.75 | GRIK1 (0.41) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL5074744 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080305066-A1 | 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour | GIVAUDAN SA (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20080305066-A1 | 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour | GIVAUDAN SA (CH) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305066-A1 | 2-C-Substituted Propane-1,3-Dicarbonyl Compounds and Their Use in Neutralising Malodour | TYR, MAL2, ACMSD | ALDH1A1 152/4885KDM4E 1182/4885TSHR 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.